293 related articles for article (PubMed ID: 22612507)
1. Correlations of TOP2A gene aberrations and expression of topoisomerase IIα protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Meng H; Chen R; Li W; Xu L; Xu L
Pathol Int; 2012 Jun; 62(6):391-9. PubMed ID: 22612507
[TBL] [Abstract][Full Text] [Related]
2. Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.
Kuo SJ; Wang BB; Chang CS; Chen TH; Yeh KT; Lee DJ; Yin PL; Chen M
Taiwan J Obstet Gynecol; 2007 Jun; 46(2):146-51. PubMed ID: 17638622
[TBL] [Abstract][Full Text] [Related]
3. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer.
Bouchalová K; Trojanec R; Kolár Z; Cwiertka K; Cernáková I; Mihál V; Hajdúch M
Neoplasma; 2006; 53(5):393-401. PubMed ID: 17013533
[TBL] [Abstract][Full Text] [Related]
4. Her-2/neu and topoisomerase IIα in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
Engelstaedter V; Schiffers J; Kahlert S; Mainka P; Engel J; Kirchner T; Diebold J; Mayr D
Diagn Mol Pathol; 2012 Jun; 21(2):77-83. PubMed ID: 22555090
[TBL] [Abstract][Full Text] [Related]
5. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study.
Kanta SY; Yamane T; Dobashi Y; Mitsui F; Kono K; Ooi A
Hum Pathol; 2006 Oct; 37(10):1333-43. PubMed ID: 16949920
[TBL] [Abstract][Full Text] [Related]
7. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies.
Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F
Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
9. [Correlation of TOP2A gene expression and survival of breast cancer patients].
Meng H; Li WC; Wang LX; Li WB; Zhang L; Fan QX; Wang RL; Lu TY
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):363-6. PubMed ID: 21875466
[TBL] [Abstract][Full Text] [Related]
10. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Varga Z; Moelans CB; Zuerrer-Hardi U; Ramach C; Behnke S; Kristiansen G; Moch H
Breast Cancer Res Treat; 2012 Jun; 133(3):929-35. PubMed ID: 22083232
[TBL] [Abstract][Full Text] [Related]
11. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
Järvinen TA; Tanner M; Bärlund M; Borg A; Isola J
Genes Chromosomes Cancer; 1999 Oct; 26(2):142-50. PubMed ID: 10469452
[TBL] [Abstract][Full Text] [Related]
12. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
13. Adenoid cystic carcinomas of the breast have low Topo IIα expression but frequently overexpress EGFR protein without EGFR gene amplification.
Vranic S; Frkovic-Grazio S; Lamovec J; Serdarevic F; Gurjeva O; Palazzo J; Bilalovic N; Lee LM; Gatalica Z
Hum Pathol; 2010 Nov; 41(11):1617-23. PubMed ID: 20688355
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
[TBL] [Abstract][Full Text] [Related]
15. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
16. [Topoisomerase IIalpha and HER2/neu gene alterations and their correlation in pancreatic ductal adenocarcinomas].
Liang ZY; Wang WZ; Gao J; Wu SF; Zeng X; Liu TH
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):102-6. PubMed ID: 17493384
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
[TBL] [Abstract][Full Text] [Related]
18. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
19. DNA topoisomerase IIalpha (TOP2A) inhibitors up-regulate fatty acid synthase gene expression in SK-Br3 breast cancer cells: in vitro evidence for a 'functional amplicon' involving FAS, Her-2/neu and TOP2A genes.
Menendez JA; Vellon L; Lupu R
Int J Mol Med; 2006 Dec; 18(6):1081-7. PubMed ID: 17089011
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
